Search results
Showing 1081 to 1095 of 1329 results for nice quality standards or clinical guidelines
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .
Evidence-based recommendations on pegunigalsidase alfa (Elfabrio) for Fabry disease (also known as alpha-galactosidase deficiency) in adults.
Topical antimicrobial dressings for locally infected leg ulcers: late-stage assessment (HTG751)
Late stage assessment (LSA) guidance on topical antimicrobial dressings for locally infected leg ulcers.
View recommendations for HTG751Show all sections
Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)
NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .
This interim process statement has been produced to guide the development of good practice guidance. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
Evidence-based recommendations on ravulizumab (Ultomiris) for treating atypical haemolytic uraemic syndrome in people weighing 10 kg or more.
Evidence-based recommendations on dasatinib (Sprycel), nilotinib (Tasigna) and high-dose imatinib (Glivec) for treating imatinib-resistant or intolerant chronic myeloid leukaemia in adults.
NICE's guidance and advice can help you make the best use of resources and generate cost savings.
This indicator covers the percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM72
Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)
Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.
Our forward view highlights the topics we will prioritise in the coming year.
Diabetes: blood pressure (without moderate or severe frailty) (IND249)
This indicator covers the percentage of patients with diabetes on the register, aged 79 years and under without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if measured in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM233
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for treating severe sickle cell disease in people 12 years and over.
This indicator covers under 75 mortality from cardiovascular disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes